Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
molecular glue
Biotech
Evommune’s $1B deal to join Novartis in molecular glue niche
Evommune paid $30 million upfront to get stuck into a niche of preclinical molecular glue degrader development that’s also being pursued by Novartis.
James Waldron
Nov 5, 2026 4:53am
Novartis sticks 2nd deal with Orionis, this one worth up to $1.4B
Jun 10, 2026 8:21am
Erasca hits ‘home run’ with cancer data but stock suffers
Apr 28, 2026 9:50am
Gilead pays Kymera $45M for preclinical protein degrader
Apr 9, 2026 8:45am
Molecular glue biotech f5 Therapeutics closes down
Mar 10, 2026 1:10pm
Fortitude has faith glue degraders can beat ADC resistance
Jan 26, 2026 10:47am
